Major players in the drug delivery devices market are F. Hoffmann-La Roche Ltd, 3M Company, Pfizer Inc, Baxter International, BD, Novartis AG, Gerresheimer AG, Johnson & Johnson Services, Inc, Bayer AG, and GlaxoSmithKline plc.
New York, May 16, 2022 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Drug Delivery Devices Global Market Report 2022" - https://www.reportlinker.com/p06277159/?utm_source=GNW The global drug delivery devices market is expected to grow from $79.68 billion in 2021 to $84.1 billion in 2022 at a compound annual growth rate (CAGR) of 5.5%. The market is expected to grow to $100.1 billion in 2026 at a compound annual growth rate (CAGR) of 4.5%. The drug delivery devices market consists of the sales of medical devices and equipment that are used for delivering specific drugs to a specific part of the body to cure chronic diseases such as cancer, infectious diseases, respiratory diseases, diabetes, cardiovascular diseases. The main route of administration of drug delivery devices are oral drug delivery, injectable drug delivery, topical drug delivery, ocular drug delivery, pulmonary drug delivery, nasal drug delivery, transmucosal drug delivery, and implantable drug delivery.Oral drug delivery is a route of drug delivery in which a tablet or capsule is administered into the alimentary canal of a human being. The patient care setting is hospitals, diagnostic centers, ambulatory surgery centers/clinics, home care settings, and others. The various applications involved are cancer, infectious diseases, respiratory diseases, diabetes, cardiovascular diseases, autoimmune diseases, central nervous system disorders, and others. North America was the largest region in the drug delivery devices market in 2021.Asia Pacific was the second-largest region in the drug delivery devices market. The regions covered in this report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. Owing to the Covid-19 pandemic. Drugs used for Covid-19 treatment are both oral and injectable; however, a marginal increase is expected for pulmonary or respiratory-based drug delivery devices. The rising prevalence of chronic diseases such as cardiovascular diseases, diabetes, cancer and other diseases is expected to drive the drug delivery devices market.According to the world health organization (WHO), by 2020, chronic diseases will account for almost three-quarters of all deaths worldwide, and that 71% of deaths due to ischemic heart disease (IHD), 75% of deaths due to stroke, and 70% of deaths due to diabetes will occur in developing countries. There are various routes of drug administration for medical drugs.The selection of the route depends on three factors - the effect desired; the type of the disease and the type of the product. Currently, the development of new drug delivery systems plays a major role in pharmaceutical industries.Research and development (R&D) in drug delivery are increasing throughout the world due to increasing prevalence of these diseases. Most of the pharmaceutical companies are focusing on multiple drug delivery technologies for creating excellent advantages and better outcome for their marketed products. Hence, the increasing prevalence of chronic diseases is resulting in increased consumption of therapeutic drugs and therapies, and this factor is expected to act as a driver for the growth of the drug delivery devices market. The regulatory changes related to medical devices is expected to restraint the growth of drug delivery devices market.The companies operating in the market are required to adapt according to the changes in the regulatory framework, which may limit business at the bottom line. Also, companies will have to bear the heavy cost of adapting to the changing regulatory framework.Also, the sudden changes in the regulatory framework related to medical devices can result in losses, fines, penalties at a global level. The new MDSAP will come into effect from 2020 and is adopted by regulators in the US, Canada, Japan, Brazil, and Australia.Following the changes, in Canada, all the medical device manufacturers including drug delivery products manufacturers, will have to comply with the requirements of MDSAP and are required to submit the MDSAP reports to the regulatory body in order to obtain or maintain the device licenses, resulting in high costs and time loss. Thus, the growth of the drug delivery devices market is limited by the regulatory changes related to medical devices. The microneedle (MN), is a highly efficient and versatile medical device technology, due to its prominent properties including painless penetration, low cost, excellent therapeutic efficacy, and relative safety.The major players operating in the global microneedle drug delivery system include, 3M, Vetter Pharma International GmbH, nano Biosciences LLC, Nano Pass and more. The microneedles are fabricated using biodegradable polymers in which drugs or vaccines are encapsulated in the microneedles.Once, the microneedles dissolve in the skin, the drug gets released. This novel delivery method allows a wider variety of molecules to pass the skin’s barrier, thus allowing the transdermal delivery to be applied to a large range of clinical applications, including diabetes, severe osteoporosis, and influenza vaccination. Companies in the drug delivery devices market are collaborating with other companies within the industry in order to strengthen their product portfolio as well as to expand their footprint across different geographies.For example, in December 2019, Leo Pharma, a Danish pharmaceutical company, has collaborated with Portal Instruments to build Portal’s advanced needle-free drug delivery system for use in conjunction with LEO Pharma’s research and approved drug portfolio. This simplifies administration and removes the need for sharp containers at home, and also decreases the time required for self-injections. In August 2020, Sulzer, a Swiss-based engineering and manufacturing firm acquired Haselmeier GmbH for $118m.The acquisition of Haselmeier will allow Sulzer to complement its healthcare portfolio, in addition to leveraging its APS expertise in precision injection moulding to expand its presence in the drug delivery devices market. Haselmeier GmbH, a Swiss-German drug delivery device developer and manufacturer. The countries covered in the drug delivery devices market are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, and USA. Read the full report: https://www.reportlinker.com/p06277159/?utm_source=GNW About Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place. __________________________
Whether you're looking for household goods at discounted prices or need to buy your grocery items in bulk, Costco is the go-to retailer for millions of shoppers across the U.S. But despite its ability to attract a loyal following, Costco has made a number of changes recently that haven't thrilled customers. In April, the warehouse retailer got rid of its special COVID hours for seniors, and just this month, Costco ended its mortgage program for members. Now, the retailer has a new warning for sh
What happened Shares of drugmaker Novavax (NASDAQ: NVAX) are up to the tune of 18.9% as of 2:11 p.m. ET Friday, according to data from S&P Global Market Intelligence, thanks to a confluence of events that work in the company's favor.
(Bloomberg) -- Bill Gates has a short position against Tesla Inc. that would now need between $1.5 billion and $2 billion to close out, Elon Musk said Friday in a series of tweets.Most Read from BloombergElon Musk Says Bill Gates Has ‘Multi-Billion Dollar’ Tesla Short PositionRussian Wins in Eastern Ukraine Spark Debate Over Course of WarFord Beats Tesla to the Punch With First Electric F-150 DeliveryBitcoin Breaks From Stocks and Keeps On Falling as Crypto SlidesZilingo’s Fired CEO Responds to
When looking for the best artificial intelligence stocks to buy, identify companies using AI technology to improve products or gain a strategic edge, such as Google, Microsoft and Nvidia.
Mirati is unlikely to carve out a share of the lung cancer market, analysts said Friday as MRTX stock collapsed on a testing disappointment.
The world has changed so much since 1985 but the price of Costco Wholesale's hot dog-and-soda special -- $1.50 -- has remained constant.
Shares of Iovance Biotherapeutics (NASDAQ: IOVA) are down 53% as of 12:24 p.m. ET Friday, according to data from S&P Global Market Intelligence, following the release of disappointing results from a pivotal melanoma drug trial released Thursday evening. Iovance had already reported solid results for melanoma treatment Lifileucel in the middle of last year, ultimately finding a response rate of 36%. This follow-on study of cancer patients with advanced melanoma who had shown improvement after previously receiving and responding to anti-PD-1/L1 therapies isn't as encouraging, with an objective response rate of only 29%.
(Bloomberg) -- Fertilizer prices that had hit records are now plunging as buyers reel from sticker shock, but that doesn’t mean the market squeeze is over. Most Read from BloombergElon Musk Says Bill Gates Has ‘Multi-Billion Dollar’ Tesla Short PositionRussian Wins in Eastern Ukraine Spark Debate Over Course of WarFord Beats Tesla to the Punch With First Electric F-150 DeliveryBitcoin Breaks From Stocks and Keeps On Falling as Crypto SlidesZilingo’s Fired CEO Responds to Questions of Mystery Pay
Eli Lilly said Friday it will unveil new test results for its biggest cancer drug, Verzenio, in June and LLY stock broke out to a fresh high.
Global car production has been hampered for months because of a plethora of supply-chain and logistics issues. Friday, Toyota Motor (ticker: TM) cut its production plans again. Toyota is taking additional downtime at some plants the week of June 6.
Retirement savers are often told they’ll see a greater return in their retirement assets if they invest it – and that may be true – but it’s important to prioritize some cash in a retirement plan as well. Retirement Tip of the Week: For those close to retirement, consider keeping a portion of your retirement plan in cash – whether that be in the portfolio itself, or in a separate account. Bank and money market accounts do not generate the same type of returns as investments, though right now with volatility some investors may beg to differ.
If you have $77,280 that you can afford to invest, these stocks can turn that into $400 in recurring monthly income.
Helium Shortage 4.0 is once again the result of a handful of unexpected supply disruptions in the heavily concentrated helium production industry—and a disastrous 1996 US law.
While the price of gasoline frequently steals all the headlines, the price of diesel is actually more important when it comes to the cost of living and the economy.
The World Health Organization says nearly 200 cases of monkeypox have been reported in more than 20 countries not usually known to have outbreaks of the unusual disease.
The stocks for companies developing cancer therapies were moving in morning trading on Friday as biotechs and researchers shared new clinical findings in advance of next week’s American Society of Clinical Oncology annual meeting. Arcellx Inc.’s (ACLX) stock jumped 11.9% after an abstract provided updated data for its CART-ddBCMA. SVB Securities analysts said in a note on Friday that they were pleased to see that the experimental therapy “continues to have a competitive efficacy signal in 24 evaluable relapsed/refractory patients.”
Stock splits have been all the rage in recent years, fueled by surging stock prices of some of the world's most recognizable companies. Worse still, the tech-heavy Nasdaq has tumbled into bear market territory, down roughly 27% from its high reached late last year. Read on to find out why they picked Amazon (NASDAQ: AMZN), Alphabet (NASDAQ: GOOGL) (NASDAQ: GOOG), and Shopify (NYSE: SHOP) from among the recent stock-split candidates.
JPMorgan expects fewer iPhone 14 units to be built in 2022 than the previous iPhone 13 model built in 2021.
The highest paid CEOs in America in 2021, according to Fortune's new analysis of executive pay.
The departure comes as the electric-truck startup is under pressure to overcome supply-chain problems that led the company to lower its production forecast for the year.